Insilico Medicine and Con மருந்து partner to accelerate drug discovery for central nervous system and autoimmune diseases

AI-driven Insilico Medicine and Con மருந்து (Con மருந்து) are collaborating on drug discovery for CNS and autoimmune diseases. The partnership will leverage Insilico's AI platform and Con மருந்து's clinical development expertise to advance at least two drug candidates, with Insilico potentially receiving significant R&D funding per project. This collaboration aims to accelerate the drug development process from discovery to market, potentially offering new treatment options to patients.